1.Spinal Muscular Atrophy Type 2 in Siblings.
Jeong Sam JEON ; Dong Hub LEE ; Byung Soo CHO ; Sa Jun CHUNG ; Chang Il AHN
Journal of the Korean Pediatric Society 1989;32(5):718-723
No abstract available.
Muscular Atrophy, Spinal*
;
Spinal Muscular Atrophies of Childhood*
2.Mitogen Activated Protein Kinase Family Proteins and c-jun Signaling in Injury-induced Schwann Cell Plasticity.
Hye Jeong LEE ; Yoon Kyung SHIN ; Hwan Tae PARK
Experimental Neurobiology 2014;23(2):130-137
Schwann cells (SCs) in the peripheral nerves myelinate axons during postnatal development to allow saltatory conduction of nerve impulses. Well-organized structures of myelin sheathes are maintained throughout life unless nerves are insulted. After peripheral nerve injury, unidentified signals from injured nerves drive SC dedifferentiation into an immature state. Dedifferentiated SCs participate in axonal regeneration by producing neurotrophic factors and removing degenerating nerve debris. In this review, we focus on the role of mitogen activated protein kinase family proteins (MAP kinases) in SC dedifferentiation. In addition, we will highlight neuregulin 1 and the transcription factor c-jun as upstream and downstream signals for MAP kinases in SC responses to nerve injury.
Action Potentials
;
Axons
;
Humans
;
Myelin Sheath
;
Nerve Growth Factors
;
Neuregulin-1
;
Peripheral Nerve Injuries
;
Peripheral Nerves
;
Phosphotransferases
;
Plastics*
;
Protein Kinases*
;
Regeneration
;
Schwann Cells
;
Transcription Factors
3.Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats.
Mi Kyoung PARK ; Ying HAN ; Mi Sun KIM ; Eunhui SEO ; Soojeong KANG ; So Young PARK ; Hyeongjong KOH ; Duk Kyu KIM ; Hye Jeong LEE
The Korean Journal of Physiology and Pharmacology 2012;16(3):181-186
Fenofibrate is a selective peroxisome proliferator-activated receptor alpha (PPARalpha) activator and is prescribed to treat hyperlipidemia. The mechanism through which PPARalpha agonists reduce food intake, body weight, and adiposity remains unclear. One explanation for the reduction of food intake is that fenofibrate promotes fatty acid oxidation and increases the production of ketone bodies upon a standard experimental dose of the drug (100~300 mg/kg/day). We observed that low-dose treatment of fenofibrate (30 mg/kg/day), which does not cause significant changes in ketone body synthesis, reduced food intake in Long-Evans Tokushima (LETO) rats. LETO rats are the physiologically normal controls for Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which are obese and cholecystokinin (CCK)-A receptor deficient. We hypothesized that the reduced food intake by fenofibrate-treated LETO rats may be associated with CCK production. To investigate the anorexic effects of fenofibrate in vivo and to determine whether CCK production may be involved, we examined the amount of food intake and CCK production. Fenofibrate-treated OLETF rats did not significantly change their food intake while LETO rats decreased their food intake. Treatment of fenofibrate increased CCK synthesis in the duodenal epithelial cells of both LETO and OLETF rats. The absence of a change in the food intake of OLETF rats, despite the increase in CCK production, may be explained by the absence of CCK-A receptors. Contrary to the OLETF rats, LETO rats, which have normal CCK receptors, presented a decrease in food intake and an increase in CCK production. These results suggest that reduced food intake by fenofibrate treatment may be associated with CCK production.
Adiposity
;
Animals
;
Body Weight
;
Cholecystokinin
;
Diethylpropion
;
Eating
;
Epithelial Cells
;
Fenofibrate
;
Hyperlipidemias
;
Ketone Bodies
;
PPAR alpha
;
Rats
;
Rats, Inbred OLETF
;
Receptor, Cholecystokinin A
;
Receptors, Cholecystokinin